stockportfolio.pro
Stocks / NEO vs STAA
NEO vs STAA
NeoGenomics, Inc. and STAAR Surgical Company side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| NeoGenomics, Inc. (NEO) | STAAR Surgical Company (STAA) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $727.33M | $239.44M |
| Net income (latest FY) | $-108.03M | $-80.45M |
| Revenue growth (5y CAGR) | 10.4% | 7.9% |
| Net margin | -14.9% | -33.6% |
| Return on equity | -12.9% | -23.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 6 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NEO — free Open STAA — freeFrequently asked questions
Which is bigger, NEO or STAA?
NeoGenomics, Inc. is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, NEO or STAA?
Over the last five fiscal years, NeoGenomics, Inc. grew revenue faster — 10.4%/yr versus 7.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.